Merck Message Board - Msg: 24452051

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 98.00

-2.3%

11:26 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Carey Thompson who wrote (1558)	3/30/2008 6:43:13 AM
From: DewDiligence_on_SI	Read Replies (1) of 1580

Isentress has a relatively narrow FDA label: “In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents [emphasis added].” fda.gov The large addressable market in HIV is in first- and second-line therapy because many patients are now remaining on those cocktails for a decade or longer. Thus, until there are new clinical data for use in the early lines of therapy, Isentress will be relegated to being a modest-selling drug.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next